Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for allegedly misleading investors regarding its financial projections and business model following its spin-off from Labcorp [3][4]. Company Overview - Fortrea is a global clinical research organization (CRO) that assists in the development of pharmaceutical and medical device products. It was spun off from Labcorp in June 2023 and had ongoing long-term projects at that time [3]. Allegations and Financial Misrepresentation - The lawsuit claims that Fortrea overestimated the revenue from its Pre-Spin Projects for 2025, overstated cost savings from phasing out transition service agreements (TSAs), and inflated its EBITDA targets for 2025, leading to a misleadingly positive outlook on its post-spin-off business model [5]. - Specific allegations include: 1. Overestimation of revenue from Pre-Spin Projects for 2025 [5]. 2. Overstatement of cost savings from the elimination of TSAs [5]. 3. Inflated EBITDA targets for 2025 [5]. Market Reactions and Stock Performance - Following a downgrade by Jefferies on September 25, 2024, which cited weaknesses in Fortrea's CRO model and the misleading nature of its cost savings, the stock dropped over 12% [5]. - A subsequent downgrade by Baird Equity Research on December 6, 2024, after the cancellation of two conferences, led to an additional 8% decline in stock price due to concerns over Fortrea's inconsistent performance and communication [5]. - On March 3, 2025, Fortrea reported disappointing Q4 and full-year 2024 results, admitting that its revenue and EBITDA goals for 2025 were unrealistic, resulting in a stock drop of more than 25% [5].
Fortrea Holdings Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; August 1, 2025 Deadline to file Lead Plaintiff Motion